New Zeland Lysosomal Storage Disorder Drugs Market to 2032
Overview
The New Zeland Lysosomal Storage Disorder Drugs Market is expected to reach a 133.02 USD Million by 2032 and is projected to grow at a CAGR of 9.61% from 2025 to 2032.
Revenue, 2024 (USD Million)
70.00
Forecast, 2032 (USD Million)
133.02
CAGR, 2024 - 2032
9.61%
Report Coverage
New Zeland
New Zeland Lysosomal Storage Disorder Drugs Market 2018-2032 USD Million
New Zeland Lysosomal Storage Disorder Drugs Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 70.00 USD Million
- Projected Market Size (2032): 133.02 USD Million
- CAGR (2025-2032): 9.61%
Key Findings of New Zeland Lysosomal Storage Disorder Drugs Market
- The New Zeland Lysosomal Storage Disorder Drugs Market was valued at 70.00 USD Million in 2024.
- The New Zeland Lysosomal Storage Disorder Drugs Market is likely to grow at a CAGR of 9.61% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Hospital Pharmacies in Distribution Channel Segment accounted for the largest share of the market with a revenue of 49.34 USD Million
- The fastest growing segment Imiglucerase in Drugs Segment grew Fastest with a CAGR of 11.67% during the forecast period from 2024 to 2032.
New Zeland Lysosomal Storage Disorder Drugs Market Scope
New Zeland Lysosomal Storage Disorder Drugs Market Segmentation & Scope
Type of Disorder
- Others
- Krabbe Disease
- Niemann-Pick Disease
- Mucopolysaccharidosis (MPS)
- Pompe Disease
- Fabry Disease
- Gaucher Disease
Age Group
- Geriatric
- Adults
- Pediatric
Gender
- Female
- Male
Distribution Channel
- Online Pharmacies
- Drugs Stores and Retail Pharmacies
- Hospital Pharmacies
Route of Administration
- Others
- Oral
- Subcutaneous (SC)
- Intravenous (IV)
Type
- Others
- Chaperone Therapy
- Substrate Reduction Therapy (SRT)
- Enzyme Replacement Therapy (ERT)
Drugs
- Others
- Avalglucosidase Alfa
- Galsulfase
- Agalsidase Alpha
- Laronidase
- Taliglucerase Alfa
- Velaglucerase
- Alglucosidase Alpha
- Idursulfase
- Agalsidase Beta
- Imiglucerase
New Zeland Lysosomal Storage Disorder Drugs Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2023 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 70.00 USD Million |
| Market Value in 2032 | 133.02 USD Million |
| CAGR (2025-2032) | 9.61% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Type of Disorder,Age Group,Gender,Distribution Channel,Route of Administration,Type,Drugs |
Regional Insights:
-
Leading Market (2024-2032): New Zeland, leading in terms of revenue 70.00 USD Million in 2024
- Key Country: New Zeland, leading in terms of revenue with value of 70.00 USD Million in 2024.
Segments and Scope
-
New Zeland Lysosomal Storage Disorder Drugs Market to 2032, By Type of Disorder
- Gaucher Disease is the largest segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 27.00 USD Million in the year 2024.
- Gaucher Disease is the Fastest growing segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 10.42 % in forecast period 2025-2032.
-
New Zeland Lysosomal Storage Disorder Drugs Market to 2032, By Age Group
- Pediatric is the largest segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 31.79 USD Million in the year 2024.
- Pediatric is the Fastest growing segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 10.51 % in forecast period 2025-2032.
-
New Zeland Lysosomal Storage Disorder Drugs Market to 2032, By Gender
- Male is the largest segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 40.78 USD Million in the year 2024.
- Male is the Fastest growing segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 10.32 % in forecast period 2025-2032.
-
New Zeland Lysosomal Storage Disorder Drugs Market to 2032, By Distribution Channel
- Hospital Pharmacies is the largest segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 49.34 USD Million in the year 2024.
- Online Pharmacies is the Fastest growing segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 9.73 % in forecast period 2025-2032.
-
New Zeland Lysosomal Storage Disorder Drugs Market to 2032, By Route of Administration
- Intravenous (IV) is the largest segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 42.21 USD Million in the year 2024.
- Subcutaneous (SC) is the Fastest growing segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 9.07 % in forecast period 2025-2032.
-
New Zeland Lysosomal Storage Disorder Drugs Market to 2032, By Type
- Enzyme Replacement Therapy (ERT) is the largest segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 46.97 USD Million in the year 2024.
- Substrate Reduction Therapy (SRT) is the Fastest growing segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 9.47 % in forecast period 2025-2032.
-
New Zeland Lysosomal Storage Disorder Drugs Market to 2032, By Drugs
- Imiglucerase is the largest segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 18.76 USD Million in the year 2024.
- Imiglucerase is the Fastest growing segment in New Zeland Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 11.67 % in forecast period 2025-2032.
New Zeland Lysosomal Storage Disorder Drugs Market Company Share Analysis
| Company Name |
|
||
| Takeda Pharmaceutical Company Limited | |||
| Pfizer Inc. | |||
| Sanofi | |||
| BioMarin | |||
| Amicus Therapeutics, Inc. | |||
New Zeland Lysosomal Storage Disorder Drugs Market Geographical Sales Distribution, 2018-2032 USD Million
New Zeland Lysosomal Storage Disorder Drugs Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The New Zeland Lysosomal Storage Disorder Drugs Market is segmented based on Segmentation Type of Disorder,Age Group,Gender,Distribution Channel,Route of Administration,Type,Drugs.
New Zeland Lysosomal Storage Disorder Drugs Market was valued at USD 70.00(Revenue in USD Million) in 2023.
New Zeland Lysosomal Storage Disorder Drugs Market is projected to grow at a CAGR of 9.61% during the forecast period of 2024 to 2032.
The Hospital Pharmacies segment is expected to dominate the New Zeland Lysosomal Storage Disorder Drugs Market, holding a largest market share of 49.34 USD Million in 2024
New Zeland Lysosomal Storage Disorder Drugs Market Scope
New Zeland Lysosomal Storage Disorder Drugs Market Segmentation & Scope
Type of Disorder
- Others
- Krabbe Disease
- Niemann-Pick Disease
- Mucopolysaccharidosis (MPS)
- Pompe Disease
- Fabry Disease
- Gaucher Disease
Age Group
- Geriatric
- Adults
- Pediatric
Gender
- Female
- Male
Distribution Channel
- Online Pharmacies
- Drugs Stores and Retail Pharmacies
- Hospital Pharmacies
Route of Administration
- Others
- Oral
- Subcutaneous (SC)
- Intravenous (IV)
Type
- Others
- Chaperone Therapy
- Substrate Reduction Therapy (SRT)
- Enzyme Replacement Therapy (ERT)
Drugs
- Others
- Avalglucosidase Alfa
- Galsulfase
- Agalsidase Alpha
- Laronidase
- Taliglucerase Alfa
- Velaglucerase
- Alglucosidase Alpha
- Idursulfase
- Agalsidase Beta
- Imiglucerase
Frequently Asked Questions
The New Zeland Lysosomal Storage Disorder Drugs Market is segmented based on Segmentation Type of Disorder,Age Group,Gender,Distribution Channel,Route of Administration,Type,Drugs.
New Zeland Lysosomal Storage Disorder Drugs Market was valued at USD 70.00(Revenue in USD Million) in 2023.
New Zeland Lysosomal Storage Disorder Drugs Market is projected to grow at a CAGR of 9.61% during the forecast period of 2024 to 2032.
The estimated market value of the New Zeland Lysosomal Storage Disorder Drugs Market for final year is USD 133.02 (USD Million).
New Zeland Lysosomal Storage Disorder Drugs Market Company Profiling
Frequently Asked Questions
The New Zeland Lysosomal Storage Disorder Drugs Market is segmented based on Segmentation Type of Disorder,Age Group,Gender,Distribution Channel,Route of Administration,Type,Drugs.
New Zeland Lysosomal Storage Disorder Drugs Market was valued at USD 70.00(Revenue in USD Million) in 2023.
New Zeland Lysosomal Storage Disorder Drugs Market is projected to grow at a CAGR of 9.61% during the forecast period of 2024 to 2032.
The estimated market value of the New Zeland Lysosomal Storage Disorder Drugs Market for final year is USD 133.02 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.